Cooper Financial Group Has $977,000 Stock Position in Laboratory Co. of America Holdings (NYSE:LH)

Cooper Financial Group boosted its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 6.7% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 4,472 shares of the medical research company’s stock after buying an additional 282 shares during the period. Cooper Financial Group’s holdings in Laboratory Co. of America were worth $977,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Manchester Capital Management LLC grew its stake in shares of Laboratory Co. of America by 1.1% in the fourth quarter. Manchester Capital Management LLC now owns 4,159 shares of the medical research company’s stock valued at $945,000 after buying an additional 45 shares in the last quarter. Trust Investment Advisors boosted its position in Laboratory Co. of America by 1.8% during the fourth quarter. Trust Investment Advisors now owns 2,567 shares of the medical research company’s stock worth $583,000 after purchasing an additional 46 shares during the period. SP Asset Management LLC boosted its position in Laboratory Co. of America by 0.3% during the fourth quarter. SP Asset Management LLC now owns 14,992 shares of the medical research company’s stock worth $3,407,000 after purchasing an additional 46 shares during the period. Atria Wealth Solutions Inc. boosted its position in Laboratory Co. of America by 2.8% during the fourth quarter. Atria Wealth Solutions Inc. now owns 1,969 shares of the medical research company’s stock worth $448,000 after purchasing an additional 53 shares during the period. Finally, Wahed Invest LLC boosted its position in Laboratory Co. of America by 3.9% during the fourth quarter. Wahed Invest LLC now owns 1,443 shares of the medical research company’s stock worth $328,000 after purchasing an additional 54 shares during the period. 95.94% of the stock is owned by institutional investors.

Insider Buying and Selling at Laboratory Co. of America

In other news, CAO Peter J. Wilkinson sold 2,439 shares of the business’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $204.33, for a total value of $498,360.87. Following the completion of the transaction, the chief accounting officer now owns 2,087 shares in the company, valued at $426,436.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Peter J. Wilkinson sold 2,439 shares of the company’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $204.33, for a total value of $498,360.87. Following the completion of the transaction, the chief accounting officer now owns 2,087 shares of the company’s stock, valued at $426,436.71. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 2,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $210.83, for a total value of $421,660.00. Following the completion of the transaction, the executive vice president now directly owns 5,637 shares of the company’s stock, valued at approximately $1,188,448.71. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,469 shares of company stock worth $3,959,058. 0.85% of the stock is owned by insiders.

Laboratory Co. of America Stock Down 1.0 %

Shares of NYSE LH opened at $205.25 on Monday. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $234.09. The business has a 50-day simple moving average of $201.83 and a two-hundred day simple moving average of $213.31. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39. The company has a market cap of $17.30 billion, a P/E ratio of 41.30, a P/E/G ratio of 1.56 and a beta of 1.04.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.20. The company had revenue of $3.18 billion for the quarter, compared to analysts’ expectations of $3.12 billion. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. Laboratory Co. of America’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted $3.82 EPS. Research analysts anticipate that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.40%. The ex-dividend date was Friday, May 24th. Laboratory Co. of America’s payout ratio is 57.95%.

Analyst Upgrades and Downgrades

LH has been the subject of a number of research analyst reports. Robert W. Baird reduced their price objective on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a research report on Friday, April 26th. Argus raised Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a report on Monday, March 25th. StockNews.com downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating in a report on Tuesday, June 4th. Truist Financial dropped their target price on Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, April 26th. Finally, SVB Leerink assumed coverage on Laboratory Co. of America in a report on Monday, February 26th. They set an “outperform” rating and a $260.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $241.86.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).